Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis

T. Senoo, N. Hattri, N. Ishikawa, K. Hujitaka, Y. Haruta, H. Murai, N. Kohno (Minami-ku, Japan)

Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis
Session: Experimental approaches in pulmonary fibrosis
Session type: Thematic Poster Session
Number: 4214
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. Senoo, N. Hattri, N. Ishikawa, K. Hujitaka, Y. Haruta, H. Murai, N. Kohno (Minami-ku, Japan). Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Eur Respir J 2010; 36: Suppl. 54, 4214

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The regulation of plasminogen activator inhibitor-1 (PAI-1) production with dexamethasone by human lung fibroblasts
Source: Eur Respir J 2005; 26: Suppl. 49, 343s
Year: 2005

Enoxaparin reduced ventilation-induced plasminogen activator inhibitor-1
Source: Annual Congress 2009 - Crossing the line: alveolo-capillary barrier control in acute lung injury
Year: 2009



Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 suppresses allergic asthma in a murine model
Source: Annual Congress 2010 - Animal models of asthma and lung inflammation
Year: 2010

Pro-urokinase up-regulates the expression of urokinase type plasminogen activator (u-PA) in human pulmonary arterial endothelial cells
Source: Eur Respir J 2007; 30: Suppl. 51, 143s
Year: 2007

Upregulation of the gene encoding the urokinase-type plasminogen activator (uPA) in respiratory muscles of COPD patients
Source: Annual Congress 2004 - Skeletal muscle in respiratory disease
Year: 2004


The relation between plasminogen activator inhibitor-1 (PAI-1) and inflammatory markers in COPD: A possible risk factor of inflammation-induced thrombosis
Source: International Congress 2017 – Systemic and airway biomarkers
Year: 2017

LATE-BREAKING ABSTRACT: Molecular mechanisms of plasminogen activator inhibitor-1 elevation in COPD sputum
Source: Annual Congress 2012 - Cell biology and inflammatory gene expression in chronic lung disease
Year: 2012

Human lung microvascular endothelial cells (HMVEC-L) angiogenic activity is inhibited by stable plasminogen activator inhibitor-1 (PAI-1) mutants via urokinase-dependent pathway
Source: Annual Congress 2004 - Lung development and cancer
Year: 2004


Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma
Source: Eur Respir J 2016; 47:1568-1571
Year: 2016


Urokinase type plasminogen activator improves airway inflammation and mucin expression in a murine asthma model
Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung
Year: 2010

SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor growth and lung metastasis formation probably through the reduction of tumor angiogenesis
Source: Annual Congress 2011 - Progress in pathology of lung cancer
Year: 2011

Regulation of plasminogen activator activity by inflammatory mediators in lung epithelial cells
Source: Eur Respir J 2005; 26: Suppl. 49, 343s
Year: 2005

Soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in exacerbated COPD
Source: International Congress 2018 – New predictors of morbidity and mortality in COPD
Year: 2018



Plasminogen activator inhibitor-1 (PAI-1) mutations of extended half-life time inhibit angiogenic properties of human lung microvascular endothelial cells (HMVEC-L)
Source: Eur Respir J 2003; 22: Suppl. 45, 225s
Year: 2003

The effect of prostaglandin (PG) E2 and its receptor antagonists on urokinase-type plasminogen activator (uPA) production by human lung fibroblasts
Source: Eur Respir J 2006; 28: Suppl. 50, 811s
Year: 2006

Soluble urokinase-type plasminogen activator receptor in monitoring of treatment response in acute exacerbation of chronic obstructive pulmonary disease
Source: International Congress 2017 – Current challenges in COPD evaluation
Year: 2017

The mechanism of plasminogen activator inhibitor type-1 (PAI-1) Cys mutants inhibitory activity towards lung capillaries endothelial cells (HMVEC-L)
Source: Eur Respir J 2005; 26: Suppl. 49, 93s
Year: 2005

Lung fibroblasts regulate the urokinase-type plasminogen activator receptor (uPAR) expression of alveolar epithelial cells and endothelial cells
Source: Eur Respir J 2006; 28: Suppl. 50, 397s
Year: 2006

Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space
Source: ERJ Open Res, 6 (4) 00455-2020; 10.1183/23120541.00455-2020
Year: 2020



Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia
Source: ERJ Open Res, 5 (1) 00212-2018; 10.1183/23120541.00212-2018
Year: 2019